Idelalisib
- Generic Name
- Idelalisib
- Brand Names
- Zydelig
- Drug Type
- Small Molecule
- Chemical Formula
- C22H18FN7O
- CAS Number
- 870281-82-6
- Unique Ingredient Identifier
- YG57I8T5M0
- Background
Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituxi...
- Indication
用于治疗：复发慢性淋巴细胞性白血病(CLL)，与利妥昔单抗联用，在由于其他共患病将考虑对单独利妥昔单抗适当治疗患者。复发滤泡B-细胞非霍奇金淋巴瘤(FL)接受至少2次既往全身治疗患者。复发性小淋巴细胞淋巴瘤(SLL)曾至少接受2次既往全身治疗患者。
- Associated Conditions
- Relapsed Chronic Lymphocytic Leukemia, Relapsed Small Lymphocytic Lymphoma, Relapsed follicular B-cell non-Hodgkin's lymphoma
- Associated Therapies
- -
Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents
- Conditions
- Interventions
- First Posted Date
- 2017-11-21
- Last Posted Date
- 2018-12-11
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT03349346
- Locations
- 🇮🇹
Infantile Regina Margherita Hospital, Torino, Italy
🇮🇹Istituto Giannina Gaslini, Genova, Italy
🇫🇷Centre Hospitalier Régional Universitaire de Lille, Lille, France
Pembrolizumab + Idelalisib for Lung Cancer Study
- Conditions
- Interventions
- First Posted Date
- 2017-08-22
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Asha Nayak
- Target Recruit Count
- 4
- Registration Number
- NCT03257722
- Locations
- 🇺🇸
Georgia Cancer Center at Augusta University, Augusta, Georgia, United States
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
- Conditions
- Interventions
- First Posted Date
- 2016-11-22
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 310
- Registration Number
- NCT02970318
- Locations
- 🇬🇧
Research Site, Wolverhampton, United Kingdom
Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2016-11-18
- Last Posted Date
- 2022-01-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 35
- Registration Number
- NCT02968563
- Locations
- 🇩🇪
Ambulante Krebszentrum Schaubstraße, Frankfurt, Brandenburg, Germany
🇩🇪KH Maria Hilf-Franziskushaus, Mönchengladbach, Mönchengladbach, Germany
🇩🇪Klinikum Rechts der Isar der Technischen Universität München, München, Germany
Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia
- Conditions
- Interventions
- First Posted Date
- 2016-11-11
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- French Innovative Leukemia Organisation
- Target Recruit Count
- 50
- Registration Number
- NCT02962401
- Locations
- 🇫🇷
Project manager, Tours, France
Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2016-10-10
- Last Posted Date
- 2021-07-14
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT02928510
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
- Conditions
- Interventions
- First Posted Date
- 2016-06-01
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 3
- Registration Number
- NCT02787369
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: CytarabineDrug: CyclophosphamideDrug: DasatinibDrug: IdarubicinDrug: IdelalisibDrug: DexamethasoneDevice: In Vitro Kinase Inhibitor AssayDrug: Doxorubicin HydrochlorideDrug: Ponatinib HydrochlorideDrug: Ruxolitinib PhosphateDrug: Sorafenib TosylateDrug: Leucovorin CalciumDrug: Sunitinib MalateDrug: MethotrexateDrug: Methylprednisolone Sodium SuccinateBiological: RituximabDrug: Vincristine Sulfate
- First Posted Date
- 2016-05-20
- Last Posted Date
- 2020-05-26
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 7
- Registration Number
- NCT02779283
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820
- First Posted Date
- 2016-04-15
- Last Posted Date
- 2020-03-04
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 3
- Registration Number
- NCT02739360
Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant
- First Posted Date
- 2016-01-25
- Last Posted Date
- 2017-09-27
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT02662296
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.